Patients
malignancy, diabetes
SCAR, VIRAL INFECTION, PLATELET DISORDERS, CONNECTIVE TISSUE DISEASE, ATROPHIC, DIABETES
This study was a double-blind, randomized clinical trial of patients referred to the dermatology clinic from 2021 to 2022. It included ten patients with skin types 1 to 4 who had burn scars at more than one site that had been present for at least three months and were between 25 and 50 years of age. Exclusion criteria included laser treatment in the past three months, pregnancy and breastfeeding, coagulation and platelet disorders, use of anticoagulant medications, diabetes and connective tissue disease, active viral infections, history of malignancy, and use of chemotherapeutic agents. Before the start of the study, all patients were informed about the procedure and completed the informed consent form. Their information such as age, sex, location of the scar, time of its formation, and treatments received were recorded in the questionnaire. All ten participating patients had at least two burn scars on more than one extremity. The type of burn scar was an atrophic burn scar, and its extent varied among each patient. After the initial assessment, the burn scars of all patients was randomly divided into two parts, with one part considered as the intervention area and the other as the control area. The injection area had dimensions of 5 cm in length and width.